Repligen Introduces Innovative SoloVPE PLUS System for Bioprocessing

Repligen Launches the CTech™ SoloVPE™ PLUS System

Repligen Corporation (NASDAQ:RGEN), a prominent name in the life sciences sector, has unveiled its latest innovation, the CTech™ SoloVPE™ PLUS System. This cutting-edge system represents a major leap in UV-based Variable Pathlength Technology, specifically tailored for biopharmaceutical manufacturers. It is designed to provide exceptional accuracy, rapid processing, and user-friendly operation in at-line ultraviolet-visible (UV-Vis) concentration measurements, seamlessly integrating into complex biological manufacturing workflows from process development to cGMP production.

Meeting the Needs of Modern Bioprocessing

The bioprocess industry is experiencing a notable shift towards concentrated drug formulations. This evolution aims to boost efficiency and drive down production costs. In response to this growing need, the SoloVPE PLUS System employs variable pathlength spectroscopy, facilitating precise concentration measurements in under 30 seconds. This is achieved without requiring dilution or background correction, which is a significant advancement in analytical technology.

Key Features of the SoloVPE PLUS System

This newly launched technology significantly complements Repligen’s existing portfolio of process analytics tools. The SoloVPE PLUS System enhances the company’s capabilities at the line, working alongside its FlowVPX™ System and the integrated RPM™ (Real-time Process Management) TFF Systems. Key applications for the SoloVPE PLUS include measuring protein concentrations—particularly for antibody drugs—and quantifying nucleic acids and mRNA in innovative mRNA therapeutics.

Efficiency and Speed in Measurement

According to Olivier Loeillot, President and CEO, the SoloVPE PLUS System is a triumph of the development team. It advances speed, precision, and reproducibility in the measurement process, reflecting Repligen’s commitment to innovation in bioprocessing. Kola Otitoju, Senior VP and Global Head of Process Analytics, echoed this sentiment, highlighting that the system is a testament to Repligen's dedication to continual innovation that aligns with customer needs.

Advantages of the SoloVPE PLUS System

The SoloVPE PLUS System offers several distinct advantages compared to existing UV-Vis spectroscopy solutions:

• Streamlined Workflow: The SoloVPE PLUS reduces operational steps by 70%, from seven to just two, simplifying the measurement process.
• Accelerated Acquisition Speed: It doubles data collection speed, providing results in half the time when compared to the previous SoloVPE model.
• Enhanced Sensitivity and Reproducibility: The system accommodates a wide concentration range—from 0.01 mg/mL to 320 mg/mL without requiring dilution, ensuring an R² ? 0.999.
• Minimized Error-Prone Steps: Directly measuring samples negates the need for dilution or extra preparation, minimizing potential errors.
• Optimized Data Management: The integrated CTech™ ViPER™ ANLYTX Software employs SQL for efficient data storage and retrieval, alongside standardized communication protocols supporting agile bioprocessing operations.

About Repligen Corporation

As a global leader in bioprocessing innovations, Repligen Corporation focuses on developing and commercializing advanced technologies and systems to optimize manufacturing processes for biological drugs. Their commitment to "inspiring advances in bioprocessing" serves a diverse customer base, primarily comprising biopharmaceutical developers and contract development organizations (CDMOs) around the globe. The company operates its headquarters in Waltham, Massachusetts, alongside multiple manufacturing sites across the U.S. and Europe, including locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.

Contact Information for Repligen

For any inquiries, please reach out to:
Sondra S. Newman
VP, Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

Frequently Asked Questions

What is the CTech™ SoloVPE™ PLUS System?

The SoloVPE PLUS is a UV-based Variable Pathlength Technology system designed for fast and accurate concentration measurements in biopharmaceutical manufacturing.

What advantages does the SoloVPE PLUS System provide?

This system significantly reduces workflow steps, accelerates data acquisition, and enhances measurement sensitivity without requiring sample dilution.

How quickly can the SoloVPE PLUS System provide results?

The system delivers precise concentration measurements in under 30 seconds, streamlining the analysis process for manufacturers.

Who can benefit from the SoloVPE PLUS System?

Biopharmaceutical manufacturers, particularly those focusing on antibody-based drugs and mRNA therapeutics, can leverage this advanced technology for improved efficiency.

Where is Repligen headquartered?

Repligen Corporation is headquartered in Waltham, Massachusetts, with multiple manufacturing sites located in the U.S. and Europe.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.